$30M quarterly sales left behind

A new report has exposed how much money was likely left on the table when pharmas couldn't keep up with demand for GLP-1 RA drugs after they were revealed to be effective against obesity.

A drug utilisation sub committee (DUSC) outcome statement has revealed the extent of the hit that GLP-1 treatments took at the end of 2022 when shortages were at their peak .

Due to the shortage of Novo Nordisk's Ozempic and Eli Lilly's Trulicity the number of patients initiating treatment with GLP-1s fell almost two-thirds year-on-year, from 32,648 in the fourth quarter of 2021 to only 12,330 in the fourth quarter of 2022.